Back Injectables maker Maiva Pharma raises Rs 1,000 crore to set up new manufacturing unit

The fund has acquired a controlling stake with the capital infusion, making it Maiva Pharma’s first private equity fundraise. Avendus acted as the exclusive financial advisor to Maiva and its shareholders on this transaction.

The company also aims to deploy the proceeds to enhance its capabilities in sterile dosage forms including pre-filled syringes, bags, oncology and hormonal injectables, it said on Thursday.

Maiva already has a plant in Hosur producing sterile injectables in vials and lyophilized vials, with a portfolio of more than 75 products for Contract Development and Manufacturing Organization (CDMO) services, catering to over 40 customers across the US, Canada, Europe, Australia, and Latin American, it said in a statement.

“This fundraise will be used to add more vial, lyophilization, and suspension capacity and introduce new manufacturing capabilities such as prefilled syringes, cartridges and bags,” said Bhaskar Krishna, managing director and chief executive at Maiva Pharma.

Set up in 1993, Maiva Pharma focuses on contract manufacturing of sterile injectables for regulated markets.

Morgan Stanley Private Equity Asia is a leading private equity investor in the Asia-Pacific region, managing third-party money funds and investing in the region for over two decades, primarily through highly structured minority investments and control buyouts in the mid-market segment.

Private equity firm InvAscent manages assets worth $650 million across four funds, tailored for India’s small and mid-market companies across pharma, healthcare delivery, medical devices, other allied sectors.

“We believe that the injectables CDMO market is poised for strong growth and Maiva is well positioned to emerge as one of the leading independent players supplying regulated markets. Under Bhaskar’s leadership, Maiva has put in place building blocks for future growth with a customer-centric approach, sharp R&D focus and an emphasis on maintaining high quality standards,” said Nirav Mehta, managing director and co-head at Morgan Stanley Private Equity Asia.

Related Posts

Without Skipping a Beat: Surgical Robot SSiMantra powers Landmark Beating Heart Bypass

World’s 1st Dual Console Complex Robotic Beating Heart TECAB performed in India’   New Delhi: SSiMantra, the only ‘Made in India’ best in class surgical robot is as usual always…

Drug Department Raids Patna’s Govind Mitra Road Medicine Market Over Suspected Illegal Sale Of Medicines

Three teams inspected several wholesale medicine shops following complaints of sales without bills, storage irregularities and alleged illegal trading of government-supplied medicines. Patna: The Drug Department has launched an inspection…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Without Skipping a Beat: Surgical Robot SSiMantra powers Landmark Beating Heart Bypass

Without Skipping a Beat: Surgical Robot SSiMantra powers Landmark Beating Heart Bypass

Drug Department Raids Patna’s Govind Mitra Road Medicine Market Over Suspected Illegal Sale Of Medicines

Drug Department Raids Patna’s Govind Mitra Road Medicine Market Over Suspected Illegal Sale Of Medicines

‘Forthwith’ Under Drugs Act Does Not Mean Immediate Dispatch of Seized Drug Samples: Karnataka HC

‘Forthwith’ Under Drugs Act Does Not Mean Immediate Dispatch of Seized Drug Samples: Karnataka HC

A Worthy New Leader takes the Torch @Sir Ganga Ram Hospital

A Worthy New Leader takes the Torch @Sir Ganga Ram Hospital

CBI arrests two NCB staffers for demanding Rs 25 lakh bribe from a chemist in UP

CBI arrests two NCB staffers for demanding Rs 25 lakh bribe from a chemist in UP

Delhi Police bust fake Unani healthcare call centre in Pitampura; 12 arrested

Delhi Police bust fake Unani healthcare call centre in Pitampura; 12 arrested